Politics
India's Semaglutide Patent Expiration to Enable Entry of 50 Branded Generics
The expiration of India's semaglutide patent on March 20 is set to significantly impact the global obesity treatment landscape with the entry of numerous generics.
Editorial Staff
1 min read
India's semaglutide patent is scheduled to expire on March 20, allowing for the introduction of approximately 50 branded generics into the market.
This development could enhance the accessibility of weight-loss medications, potentially increasing treatment options for obesity on a global scale.
The influx of generics may also lead to competitive pricing, influencing market dynamics and healthcare strategies in various regions.